COVID-19 and Autoimmune Liver Diseases
Open Access
- 10 May 2022
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (10) , 2681
Abstract
SARS-CoV-2 infection can trigger autoimmune responses, either by a systemic hyperstimulation of the immune system or molecular mimicry (or both). We here summarize the current knowledges about autoimmune liver diseases (AILDs) and COVID-19, focusing on (a) the risk of SARS-CoV-2 infection in patients affected by AILDs and/or under pharmacological treatment with immunosuppressants; (b) the capability of vaccination against SARS-CoV-2 to trigger autoimmune responses in the liver; and (c) the efficacy of vaccines against SARS-CoV-2 in patients with AILDs. Although unconclusive results have been obtained regarding the risk of being infected by SARS-CoV-2, generally indicating that all patients with chronic liver diseases have the same risk, irrespective of the etiology, the use of immunosuppressants in patients with AILDs seems to be correlated to COVID-19 severity. Few cases of autoimmune hepatitis (AIH) after SARS-CoV-2 vaccination have been reported, all characterized by a complete remission upon steroid treatment, but further evidence is needed to demonstrate the causality assessment. Humoral responses have been observed in patients with AILDs upon vaccination. In conclusion, the link between SARS-CoV-2 infection and AILDs is far to be completely elucidated. In these patients, the use of immunosuppressants has been correlated to an increase of disease severity and lower levels of antibodies upon vaccination.Keywords
This publication has 44 references indexed in Scilit:
- Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, ChinaClinical Infectious Diseases, 2020
- Evaluation of classical and novel autoantibodies for the diagnosis of Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome (PBC-AIH OS)PLOS ONE, 2018
- Factors Associated With Response to Therapy and Outcome of Patients With Primary Biliary Cirrhosis With Features of Autoimmune HepatitisClinical Gastroenterology and Hepatology, 2014
- Smell and Autoimmunity: A Comprehensive ReviewClinical Reviews in Allergy & Immunology, 2012
- Antinuclear antibodies as ancillary markers in primary biliary cirrhosisExpert Review of Molecular Diagnostics, 2012
- Diagnosis and Therapy of Autoimmune HepatitisMini-Reviews in Medicinal Chemistry, 2009
- The Serological Profile of the Autoimmune Hepatitis/Primary Biliary Cirrhosis Overlap SyndromeAmerican Journal of Gastroenterology, 2009
- Antinuclear antibodies giving the ‘multiple nuclear dots’ or the ‘rim‐like/membranous’ patterns: diagnostic accuracy for primary biliary cirrhosisAlimentary Pharmacology & Therapeutics, 2006
- Early Enhanced Expression of Interferon-Inducible Protein-10 (CXCL-10) and Other Chemokines Predicts Adverse Outcome in Severe Acute Respiratory SyndromeClinical Chemistry, 2005
- Clinical features of type 1 autoimmune hepatitis in elderly Italian patientsAlimentary Pharmacology & Therapeutics, 2005